Cardiff Oncology, Inc. (CRDF) stock
Close on Nov 18, 2026Market cap $65.27MP/E –Yield –
Cardiff Oncology, Inc. saw revenue fall 7.0% to $508.00K over the twelve months to Jun 30, 2026. Free cash flow was -$37.97M. At the latest close the market valued the company at $65.27M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $65.27M
- P/E ratio
- –
- Price to sales
- 128.49
- Price to book
- 2.46
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $508.00K
- Net income
- -$40.05M
- EPS, diluted
- -$0.60
- Free cash flow
- -$37.97M
- Book value per share
- $0.39
- Diluted shares
- 68M
Trading
- Previous close
- $0.85
- Open
- $0.84
- Day's range
- $0.81 – $0.88
- Volume
- 864,756
- Average volume (20 days)
- 1,731,921
- Beta (5 years)
- 1.58
- 52-week range
- $0.71 – $3.31
- RSI (14 days)
- 45.8
- Volatility (1 year)
- 89.4%
- Relative volume
- 0.75×
- WACC
- 13.0%
Market cap history
Month-end market cap since 2012, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 18, 2026. The S&P 500 is measured by the SPY fund.
| Period | CRDF | S&P 500 | Difference | CRDF per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -6.9% | -4.3% | −2.6 pts | ||
| 3 months | -5.3% | -4.6% | −0.7 pts | ||
| Year to date | -70.1% | +7.9% | −78.1 pts | ||
| 1 year | -58.9% | +11.8% | −70.7 pts | ||
| 3 years | -30.1% | +68.0% | −98.0 pts | -11.2% | +18.9% |
| 5 years | -86.5% | +66.2% | −152.7 pts | -33.0% | +10.7% |
| 10 years | -99.6% | +291.3% | −391.0 pts | -43.1% | +14.6% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Cardiff Oncology filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Update
- Update
- Results
- News
- Update
About Cardiff Oncology
Biological Products, (No Diagnostic Substances)
The company is a clinical-stage biotechnology firm that develops cancer therapies by targeting polo-like kinase 1 inhibition. It operates in a single business segment dedicated to oncology drug development. Its primary drug candidate is onvansertib, an oral small-molecule inhibitor tested in combination with standard medical treatments. The company focuses clinical programs on patients diagnosed with various malignancies, including RAS-mutated metastatic colorectal cancer, metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, metastatic triple-negative breast cancer, and chronic myelomonocytic leukemia.
Company profile, executives and historyCardiff Oncology stock: common questions
What is Cardiff Oncology's stock price?
CRDF closed at $0.84 on Nov 18, 2026, down 0.87% on the day. Over the past 52 weeks it traded between $0.71 and $3.31.
What is Cardiff Oncology's market cap?
Cardiff Oncology was worth $65.27M at the close on Nov 18, 2026: the share price times the diluted shares outstanding.
What is CRDF's P/E ratio?
Cardiff Oncology lost money over the twelve months to Jun 30, 2026 (diluted EPS -$0.60), so it has no meaningful P/E ratio.
How much revenue does Cardiff Oncology make?
Cardiff Oncology reported revenue of $508.00K for the twelve months to Jun 30, 2026, down 7.0% from a year earlier.
Does Cardiff Oncology pay a dividend?
No. Cardiff Oncology has not paid a cash dividend over the last twelve months.
How has CRDF stock performed over the past year?
Including dividends, CRDF returned -58.9% over the past year, against +11.8% for the S&P 500.
How many CRDF shares are sold short?
12M shares were sold short at the latest FINRA report, 16.58% of the float, or 30.8 days of average trading volume.
Who are Cardiff Oncology's competitors?
Companies most similar to Cardiff Oncology by business, industry and size include PALI, CMPX, ALLR, ONCO, XCUR.
See a number that looks wrong?